At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
A research team at Oregon Health & Science University (OHSU) has discovered a promising new drug combination that may help people with acute myeloid leukaemia overcome resistance to one of the most ...
Marine biologists sampling coral reef waters multiple times a day have shown how they shape surrounding marine life.
In an era where precision medicine is redefining patient outcomes, cell separation technologies—encompassing the isolation of ...
The limits of conventional bathing water monitoring are becoming harder to ignore.Many of these sites sit close to treated ...
The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...
The immune system provides constant surveillance for the body, aiming to spot and eliminate disease-causing microbes or ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.
CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...
During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback